Below is our resent interview with Alastair Moore, Investor and advisor at Clerkenwell Health:
Q: Could you provide our readers with a brief introduction to your company?
A: Clerkenwell Health is a Commercial Psychedelic-Speciality Contract Research Organisation (CRO) and first company of its kind to offer bespoke clinical trial design and delivery services to the 70+ psychedelic drug manufacturers running Phase I-III studies.
Q: Any highlights on your recent announcement?
A: Octarine Bio is a synthetic biology drug development company that produces psilocybin from sugar using fermentation. They have partnered with Clerkenwell Health to help design and deliver their trials from the UK. This is one of the first cross-border commercial agreements within the European psychedelics sector and ushers in the next wave of commercially-led research for this nascent industry.
Q: Can you give us more insights into your offering?
A: Clerkenwell offer the full suite of clinical trial support services to its customers. This includes everything from early stage scientific and regulatory strategy advice through to the design and delivery of clinical trials. Clerkenwell has been created specifically to service the psychedelics industry so have built a team with significant experience working with these compounds and are developing a research site designed to optimise the psychedelic experience and thereby enhance patient outcomes.
Q: What can we expect from your company in the next 6 months? What are your plans?
A: We are in discussions with a number of exciting international psychedelic drug developers about running trials with them so we are focused on delivering clinical services to them and our existing clients.We are also currently fundraising. This round will allow us to further build out our clinical team, launch our therapist training programme and to develop our research Centre of Excellence for the delivery of these trials.
Q: What is the best thing about your company that people might not know about?
A: Our team has a heritage in the drug policy and psychedelics field combined with innovative pharmaceutical / healthcare backgrounds, which uniquely positions us for this disruptive new sector.Our founders have worked at The Beckley Foundation (the UK’s leading psychedelic research institute), IQVIA (world leading CRO), Compass Pathways (World leading psilocybin developer), Hanway Associates (the preeminent European cannabis consultancy) and within Accenture’s UK pharma team.